Literature DB >> 10337541

Inflammatory status as a main determinant of outcome in patients with unstable angina, independent of coagulation activation and endothelial cell function.

P W Verheggen1, M P de Maat, V M Cats, F Haverkate, A H Zwinderman, C Kluft, A V Bruschke.   

Abstract

AIMS: Inflammation, endothelial cell function and the coagulation system have been demonstrated to be involved in the onset and course of unstable angina. Whether a proinflammatory state independently determines outcome is unknown and has not been determined yet in a clinically well defined study population of consecutive patients admitted with unstable angina. METHODS AND
RESULTS: Markers of inflammation, coagulation activation and endothelial cell function were determined on admission in blood of 211 consecutive patients with severe unstable angina and were related to the in-hospital course. Refractory unstable angina occurred in 76 patients (36%) during their hospital stay. In a univariate analysis, C-reactive protein (P = 0.03), fibrinogen (P < 0.001) and erythrocyte sedimentation rate (P = 0.001) levels were significantly higher in patients with refractory unstable angina, when compared with patients who had an uneventful clinical course. The odds ratios (95% CI) adjusted for age, sex, body mass index, smoking behaviour and cholesterol levels of the occurrence of refractory unstable angina for patients in the highest quartile compared with patients in the lowest quartile of inflammatory markers were 2.19 (0.94-5.11) for C-reactive protein, 2.83 (1.13-7.10) for fibrinogen and 4.72 (1.70-13.09) for the erythrocyte sedimentation rate. The findings were not affected by the presence or absence of myocardial necrosis or the interval between onset of angina and blood collection. No association was found between markers of coagulation activation or markers of endothelial cell function, and in-hospital outcome.
CONCLUSION: We found that in a clinically well-defined study population of patients with severe unstable angina, a proinflammatory state is an important and independent determinant of short-term outcome. The data strengthen the importance of inflammation in this syndrome.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10337541     DOI: 10.1053/euhj.1998.1312

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  10 in total

1.  Drug-disease interactions: reduced beta-adrenergic and potassium channel antagonist activities of sotalol in the presence of acute and chronic inflammatory conditions in the rat.

Authors:  K M Kulmatycki; K Abouchehade; S Sattari; F Jamali
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

2.  Dietary patterns are linked to cardiovascular risk factors but not to inflammatory markers in Alaska Eskimos.

Authors:  Sigal Eilat-Adar; Mihriye Mete; Elizabeth D Nobmann; Jiaqiong Xu; Richard R Fabsitz; Sven O E Ebbesson; Barbara V Howard
Journal:  J Nutr       Date:  2009-10-14       Impact factor: 4.798

3.  Cardiovascular effect of inflammation and nonsteroidal anti-inflammatory drugs on renin-angiotensin system in experimental arthritis.

Authors:  Waheed Asghar; Ali Aghazadeh-Habashi; Fakhreddin Jamali
Journal:  Inflammopharmacology       Date:  2017-04-07       Impact factor: 4.473

4.  Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis.

Authors:  P R Mayo; K Skeith; A S Russell; F Jamali
Journal:  Br J Clin Pharmacol       Date:  2000-12       Impact factor: 4.335

Review 5.  Fibrinogen and coronary risk.

Authors:  W Koenig
Journal:  Curr Cardiol Rep       Date:  1999-07       Impact factor: 2.931

6.  Clinical, electrocardiographic, and biochemical data for immediate risk stratification in acute coronary syndromes.

Authors:  S Savonitto; R Fusco; C B Granger; M G Cohen; T D Thompson; D Ardissino; R M Califf
Journal:  Ann Noninvasive Electrocardiol       Date:  2001-01       Impact factor: 1.468

Review 7.  Critical appraisal of C-reactive protein throughout the spectrum of cardiovascular disease.

Authors:  Raed Osman; Philippe L L'Allier; Nader Elgharib; Jean-Claude Tardif
Journal:  Vasc Health Risk Manag       Date:  2006

8.  Exploring the association of fibrinogen and CRP with the clinical spectrum of CAD and periprocedural outcomes in patients undergoing percutaneous coronary interventions.

Authors:  Vijay Khandelwal; Aditya Kapoor; Danish Kazmi; Archana Sinha; Shiridhar Kashyap; Roopali Khanna; Sudeep Kumar; Naveen Garg; Satyendra Tewari; Ankit Sahu; Pravin Goel
Journal:  Ann Card Anaesth       Date:  2022 Jan-Mar

9.  Blood fibrinogen level as a biomarker of adverse outcomes in patients with coronary artery disease: A systematic review and meta-analysis.

Authors:  Zhanqian Cui; Guowei Zhao; Xi Liu
Journal:  Medicine (Baltimore)       Date:  2022-08-19       Impact factor: 1.817

10.  Elevated Baseline Serum Fibrinogen: Effect on 2-Year Major Adverse Cardiovascular Events Following Percutaneous Coronary Intervention.

Authors:  Lawrence Ang; Omid Behnamfar; Samhita Palakodeti; Felice Lin; Ali Pourdjabbar; Mitul P Patel; Ryan R Reeves; Ehtisham Mahmud
Journal:  J Am Heart Assoc       Date:  2017-11-18       Impact factor: 5.501

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.